Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Celecoxib helps prevent restenosis and appears safe

17.08.2007
Adjunctive use of the COX-2 inhibitor celcoxib after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion, conclude authors of an Article published in this week’s Cardiology Special Issue of The Lancet.

But an accompanying Comment warns that clinical trials suggest long-term use of celecoxib can expose patients to an additional risk of heart attack.

Dr Hyo-Soo Kim, Seoul National University Hospital, Seoul, South Korea and colleagues have published the results of the COREA-TAXUS trial, which aimed to test whether the COX-2 inhibitor celecoxib could prevent the formation of smooth muscle tissue (neointima) within stents, which can lead to narrowing and eventually re-blockage of the lumen of the stent (restenosis).

They studied 274 patients, all of whom were given aspirin (100mg) daily and clopidogrel (75mg daily). Of these, 136 were randomly assigned to receive celecoxib (400mg before the stent implantation, and then 200mg twice daily for 6 months after the procedure). The in-stent lumen diameter of all patients was measured using a coronary angiography six months after stent implantation.

The researchers found that the average reduction on in-stent luminal diameter was 0.49mm in the celecoxib group and 0.75mm in the control group, meaning that celecoxib reduced the luminal reduction by 35%. There was also a decreased need for target-lesion revascularisation in the celecoxib group.

The authors say: “These data suggest that the adjunctive use of celecoxib for 6 months after stent implantation in patients with coronary artery is safe.” They add that unlike with another COX-2 inhibitor rofecoxib, celecoxib does not increase the risk of cardiovascular events. They say: “Administration of celecoxib for 6 months does not seem to increase the risk of adverse cardiac events in the intermediate term when used with dual anti-platelet therapy. We will be interested to see the 2-5 year follow-up results of this cohort.”

In the accompanying Comment, Drs Francesco Pelliccia and Vincenzo Pasceri, Interventional Cardiology Unit, Ospedale San Filippo Neri, Rome, Italy say that the safety of celecoxib needs to be confirmed by studies to assess risk of heart attack and cardiac death, and that gastrointestinal tolerability of celecoxib in combination with aspirin and clopidogrel could also be a drawback.

However the Comment authors conclude: “The study by Koo and colleagues underscores that systemic therapy might still have a role in prevention of restenosis, even in the era of drug-eluting stents.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/celecoxib.pdf

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>